MedTrace Logo

Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers

NCT01685671 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2017-05-23

No results posted yet for this study

Summary

The purpose of this study is to investigate the pharmacokinetics of CKD-11101 and NESP after SC administration in health male volunteers

Conditions

Interventions

DRUG

NESP 60μg

Administrated NESP 60μg once subcutaneously

DRUG

CKD-11101 60μg

Administrated CKD-11101 60μg once subcutaneously

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Kyung Sang Yu, Ph.D · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-26
Primary Completion
2012-12-25
Completion
2013-01-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01685671 on ClinicalTrials.gov